Post-Diagnosis Aspirin Use Not Linked with Breast Cancer-Specific Mortality

Share this content:

the Cancer Therapy Advisor take:

Post-diagnosis initiation of aspirin use in women with breast cancer was not linked to a decline in breast cancer-specific mortality, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.

The study included women between the ages of 50 to 80 who were diagnosed with stage I-III breast cancer.  The women were chosen from Ireland’s National Cancer Registry (N = 4,540) and the information about the initiation of the post-diagnosis aspirin use was gathered from linked national prescription refill data (N =764).

Modified hazard ratios (HRs) were approximated for correlations between de novo post-diagnosis aspirin use and all-cause, breast cancer-specific mortality.

Results revealed that the median time from breast cancer diagnosis to de novo aspirin initiation was 1.8 years.  A majority of the women (95%) was taking less than 150 mg/day and the days’ supply of aspirin received had a mean value of 631.

No relationship was found between de novo aspirin use and breast cancer specific mortality (HR, 0.98; 95% CI:, 0.74, 1.30).

Similarly, no association was found in women taking high-intensity doses of aspirin (HR, 1.03; 95% CI: 0.72, 1.47) or women initiating de novo aspirin in the 1.5 years after diagnosis (HR, 1.04; 95% CI: 0.77, 1.40).

This study suggests further analysis and understanding of aspirin’s mechanism of action be conducted to help design future studies in breast cancer.

Low-dose Aspirin Use Has Potential to Lower Pancreatic Cancer Risk
Post-diagnosis initiation of aspirin use in women with breast cancer was not linked to a decline in breast cancer-specific mortality.
Aspirin use has been associated with significant reductions in breast cancer-related mortality in some observational studies. However, these studies included women who initiated aspirin use before breast cancer diagnosis.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs